BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
42 hedge funds and large institutions have $17.1M invested in BRAINSTORM CELL THERAPUTC in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 9 closing their positions.
739% more call options, than puts
Call options by funds: $3.65M | Put options by funds: $435K
56% more capital invested
Capital invested by funds: $11M → $17.1M (+$6.13M)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
0.02% less ownership
Funds ownership: 0.73% → 0.71% (-0.02%)
13% less funds holding
Funds holding: 48 → 42 (-6)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$192K |
| 2 |
TIAM2
Tru Independence Asset Management 2
Portland,
Oregon
|
+$147K |
| 3 |
Renaissance Technologies
New York
|
+$129K |
| 4 |
Millennium Management
New York
|
+$112K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$516K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$212K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$80.7K |
| 4 |
SCFS
S.C. Financial Services
Scottsdale,
Arizona
|
-$70K |
| 5 |
VF
Virtu Financial
New York
|
-$57K |
BCLI Hedge Fund Activity: Q3 2022 in Review
42 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2022, worth a combined $17.1M — up 56% from $11M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BCLI and 4 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 13 added.
The largest buyer was Raymond James & Associates, adding an estimated $192K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $516K sold.
- 42 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2022, down from 48 in Q2 2022.
- Funds reported $17.1M of BRAINSTORM CELL THERAPUTC stock for Q3 2022, up 56% quarter-over-quarter.
- 4 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2022 and 9 closed out, a net change of -5 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2022 was Raymond James & Associates, an estimated $192K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2022 was JP Morgan Chase, an estimated $516K sold.
Based on aggregated 13F filings for Q3 2022.